Menadione (vitamin K3), which is not used as a nutritional supplemental form of vitamin K for humans, has been reported to cause adverse reactions, including hemolytic anemia. Large doses have also been reported to cause brain damage.
A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Orlistat | Orlistat can cause a decrease in the absorption of Menadione resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Alpha-1-proteinase inhibitor | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Menadione. |
| Tranexamic acid | Menadione may increase the thrombogenic activities of Tranexamic acid. |
| Aminocaproic acid | Menadione may increase the thrombogenic activities of Aminocaproic acid. |
| Aprotinin | Menadione may increase the thrombogenic activities of Aprotinin. |
| Hydrogen peroxide | Menadione may increase the thrombogenic activities of Hydrogen peroxide. |
| Aminomethylbenzoic acid | Menadione may increase the thrombogenic activities of Aminomethylbenzoic acid. |
| Camostat | Menadione may increase the thrombogenic activities of Camostat. |
| Menadione bisulfite | Menadione may increase the thrombogenic activities of Menadione bisulfite. |
| Fibrinogen human | The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Menadione. |
| Tretinoin | The risk or severity of Thrombosis can be increased when Menadione is combined with Tretinoin. |
| Antihemophilic factor, human recombinant | Menadione may increase the thrombogenic activities of Antihemophilic factor, human recombinant. |
| Coagulation factor VIIa Recombinant Human | Menadione may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human. |
| Coagulation Factor IX (Recombinant) | Menadione may increase the thrombogenic activities of Coagulation Factor IX (Recombinant). |
| Calcium | Menadione may increase the thrombogenic activities of Calcium. |
| Pantothenic acid | Menadione may increase the thrombogenic activities of Pantothenic acid. |
| Formic acid | Menadione may increase the thrombogenic activities of Formic acid. |
| Platelet Activating Factor | Menadione may increase the thrombogenic activities of Platelet Activating Factor. |
| Turoctocog alfa | Menadione may increase the thrombogenic activities of Turoctocog alfa. |
| Catridecacog | Menadione may increase the thrombogenic activities of Catridecacog. |
| Antihemophilic factor (recombinant), PEGylated | Menadione may increase the thrombogenic activities of Antihemophilic factor (recombinant), PEGylated. |
| Prothrombin | Menadione may increase the thrombogenic activities of Prothrombin. |
| Factor IX Complex (Human) | Menadione may increase the thrombogenic activities of Factor IX Complex (Human). |
| Susoctocog alfa | Menadione may increase the thrombogenic activities of Susoctocog alfa. |
| Eftrenonacog alfa | Menadione may increase the thrombogenic activities of Eftrenonacog alfa. |
| Rusalatide acetate | Menadione may increase the thrombogenic activities of Rusalatide acetate. |
| Vatreptacog alfa | Menadione may increase the thrombogenic activities of Vatreptacog alfa. |
| Factor XIII (human) | Menadione may increase the thrombogenic activities of Factor XIII (human). |
| Von Willebrand factor human | Menadione may increase the thrombogenic activities of Von Willebrand factor human. |
| Coagulation factor X human | Menadione may increase the thrombogenic activities of Coagulation factor X human. |
| Coagulation factor VII human | Menadione may increase the thrombogenic activities of Coagulation factor VII human. |
| Anti-inhibitor coagulant complex | Menadione may increase the thrombogenic activities of Anti-inhibitor coagulant complex. |
| Coagulation Factor IX Human | Menadione may increase the thrombogenic activities of Coagulation Factor IX Human. |
| Antihemophilic factor human | Menadione may increase the thrombogenic activities of Antihemophilic factor human. |
| Kallidinogenase | Menadione may increase the thrombogenic activities of Kallidinogenase. |
| Trenonacog alfa | Menadione may increase the thrombogenic activities of Trenonacog alfa. |
| Albutrepenonacog alfa | Menadione may increase the thrombogenic activities of Albutrepenonacog alfa. |
| Emicizumab | Menadione may increase the thrombogenic activities of Emicizumab. |
| Nonacog beta pegol | Menadione may increase the thrombogenic activities of Nonacog beta pegol. |
| Moroctocog alfa | Menadione may increase the thrombogenic activities of Moroctocog alfa. |
| Beroctocog alfa | Menadione may increase the thrombogenic activities of Beroctocog alfa. |
| Andexanet alfa | Menadione may increase the thrombogenic activities of Andexanet alfa. |
| Calcium cation | Menadione may increase the thrombogenic activities of Calcium cation. |
| Damoctocog alfa pegol | Menadione may increase the thrombogenic activities of Damoctocog alfa pegol. |
| Turoctocog alfa pegol | Menadione may increase the thrombogenic activities of Turoctocog alfa pegol. |
| Alteplase | The therapeutic efficacy of Menadione can be decreased when used in combination with Alteplase. |
| Urokinase | The therapeutic efficacy of Menadione can be decreased when used in combination with Urokinase. |
| Reteplase | The therapeutic efficacy of Menadione can be decreased when used in combination with Reteplase. |
| Anistreplase | The therapeutic efficacy of Menadione can be decreased when used in combination with Anistreplase. |
| Tenecteplase | The therapeutic efficacy of Menadione can be decreased when used in combination with Tenecteplase. |
| Streptokinase | The therapeutic efficacy of Menadione can be decreased when used in combination with Streptokinase. |
| Lanoteplase | The therapeutic efficacy of Menadione can be decreased when used in combination with Lanoteplase. |
| Amediplase | The therapeutic efficacy of Menadione can be decreased when used in combination with Amediplase. |
| Saruplase | The therapeutic efficacy of Menadione can be decreased when used in combination with Saruplase. |
| Protein S human | Menadione may increase the thrombogenic activities of Protein S human. |
| Rurioctocog alfa pegol | Menadione may increase the thrombogenic activities of Rurioctocog alfa pegol. |
| Etranacogene dezaparvovec | Menadione may increase the thrombogenic activities of Etranacogene dezaparvovec. |